Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M

Alaunos Therapeutics, Inc.

ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
Liver weight reduced 43% (p<0.0001); lower ALT, AST, ALP and improved histology in treated animals.
Favorable body composition shift: fat -44.6% (grams), lean +17.2% as % body weight (high dose).
Cash and cash equivalents $0.354M as of March 31, 2026; runway into Q2 2026, needs additional financing.
Data from non-GLP mouse studies only; ALN1003 has not been tested in humans.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-238237
form_type: 8-K
ticker: TCRT
cik: 0001107421
company_name: Alaunos Therapeutics, Inc.
filed_at: 2026-05-26T15:00:21+00:00
discovered_at: 2026-05-26T15:02:00.299303+00:00
generated_at: 2026-05-26T15:02:37.902818+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-238237
json_url: https://secwatch.observer/filing/0001193125-26-238237.json
markdown_url: https://secwatch.observer/filing/0001193125-26-238237.md
text_url: https://secwatch.observer/filing/0001193125-26-238237.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/0001193125-26-238237-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/tcrt-20260526.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-238237

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.